Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
After two years of dedicated and persistent advocacy by ADI, dementia will, for the first time, be formally recognised within the new UN Political Declaration on noncommunicable diseases (NCDs) and mental health, as a leading NCD.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Lecanemab represents the second antibody treatment for Alzheimer’s disease to not be recommended marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease. Donanemab is the…
Regional Director for the Americas, Diego Aguilar, alongside politician and neuroscientist Facundo Manes, and ADI’s Argentinian member association A.L.M.A, joined for urgent action on dementia following steeply increasing dementia forecasts and stalling progress towards a National Dementia Plan in the country.
In recent events, ADI Regional Director for Asia-Pacific, DY Suharya, was invited to contribute to key summits, events and meetings, with a key focus on improving dementia care, innovating dementia technology and advising on advocacy across the Asia-Pacific region and beyond.
ADI is sharing a round-up of our recent action in Europe, on advocacy and research, with ADI Board Vice Chair, Meera Pattabiraman, and ADI Director of Research and Publications, Wendy Weidner. Both taking part in vital dialogues in June 2024.
In under a year, Brazil has made giant leaps in the development of its own National Dementia Plan, culminating in legislation signed by President Luiz Inácio Lula da Silva on 4 June, 2024. ADI revisits the journey that we have shared with our Brazilian member association, Febraz, to help make this plan a reality.
In May 2024, the ADI delegation returned to Geneva, Switzerland, for the World Health Organization’s 77th annual World Health Assembly to launch ’From Plan To Impact VII: Dementia at a crossroads’. Read ADI's highlights from the event.
In April 2024, the world's longest-running global conference on Alzheimer's disease and dementia came to Kraków, Poland, to provide the latest insights, innovations and inspirations on dementia over three days, six plenary sessions, 29 parallel sessions and eight symposiums to over 1000 delegates representing over 100 countries.